bluebird bio Inc (NAS:BLUE)
$ 0.405 0.0272 (7.2%) Market Cap: 78.75 Mil Enterprise Value: 376.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

bluebird bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 12:50PM GMT
Release Date Price: $21.24 (+2.60%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Thank you, everyone. We are live. Good morning, everyone. Thanks for joining us. I'm pleased to have bluebird bio with us this morning. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs.

With us from bluebird, we have Nick Leschly, CEO; Chip Baird, CFO; Philip Gregory, CSO; Andrew Obenshain, President, Severe Genetic Diseases; and Nicola Heffron, COO, Oncology.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

With that, Nick, maybe to start here, bluebird is separating into 2 businesses: one focused on severe genetic diseases and one on oncology and this is anticipated to complete by the end of the year.

To start, can you walk us through where that process stands and what underlies the decision to form 2 separate companies and how you're thinking about the splits in terms of infrastructure here?

Nick Leschly
bluebird bio, Inc. - President, CEO & Director

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot